A Multiple-Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of ABT-354 in Subjects With Mild-to-Moderate Alzheimer's Disease on Stable Doses of Acetylcholinesterase Inhibitors
Latest Information Update: 16 Dec 2013
At a glance
- Drugs SLV 354 (Primary)
- Indications Alzheimer's disease
- Focus Adverse reactions
- 01 Nov 2013 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 02 Aug 2013 New trial record